Beyond these experimentally validated cancers, our study observed differential ALYREF expression in most cancers and its prognostic potential in KICH, KIRP, PRAD, ACC, ESCA, CHOL, MESO, and DLBC, particularly in urinary tumors. Here, ALYREF is linked to cancer.